Determinants of mortality in patients with type 2 diabetes: a review

Reviews in Endocrine and Metabolic Disorders

Volumn 17, Issue 1, 2016, Pages 129-137

  Engelmann, Jana ^a   Manuwald, Ulf ^a   Rubach, Constanze ^a   Kugler, Joachim ^a   Birkenfeld, Andreas L ^b,c   Hanefeld, Markolf ^c   Rothe, Ulrike ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Determinants; Life expectancy; Lifetime; Mortality; Survival; T2DM

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; C PEPTIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLASMA PROTEIN; TESTOSTERONE; TRIACYLGLYCEROL;

ALCOHOL ABUSE; ANEMIA; ANKLE BRACHIAL INDEX; BODY MASS; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COLD; COMORBIDITY; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; DYSGLYCEMIA; DYSLIPIDEMIA; EDUCATIONAL STATUS; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEALTH CARE ACCESS; HEART FAILURE; HEART INFARCTION; HEAT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LOWEST INCOME GROUP; MORTALITY; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; POVERTY; QT PROLONGATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; RURAL AREA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOCIAL STATUS; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; AGED; EPIDEMIOLOGY; EUROPE; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84962915337     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-016-9349-0     Document Type: Review

References (137)

1. WHO. Global status report on noncommunicable diseases 2014. Switzerland 2014. 298 p
2. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF diabetes Atlas: sixth edition 6th ed. Guariguata L, Nolan T, Beagley J, Linnenkamp U, Jacqmain O, editors. International Diabetes Federation: Basel; 2013. 155 p.
3. Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, et al. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. PLoS ONE. 2015;10(4):e0123116.
4. Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care. 2013;36(9):2582–90.
5. Jones DA, Gallagher S, Rathod KS, Redwood S, de Belder MA, Mathur A, et al. Mortality in South Asians and Caucasians after percutaneous coronary intervention in the United Kingdom: an observational cohort study of 279,256 patients from the BCIS (British cardiovascular intervention Society) National Database. JACC Cardiovasc Interv. 2014;7(4):362–71.
6. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–8.
7. Gordon-Dseagu VL, Shelton N, Mindell J. Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the health Survey for England and Scottish health Survey cohorts. J Diabetes Complicat. 2014;28(6):791–7.
8. Chiang HH, Tseng FY, Wang CY, Chen CL, Chen YC, See TT, et al. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS ONE. 2014;9(10):e109501.
9. Hanefeld M, Pistrosch F, Schulze J, Rothe U. The metabolic syndrome and cardiovascular diseases: an Update of medical treatment. J Metabolic Synd. 2014;3:160.
10. Cox AJ, Hugenschmidt CE, Wang PT, Hsu FC, Kenchaiah S, Daniel K, et al. Usefulness of biventricular volume as a predictor of mortality in patients with diabetes mellitus (from the diabetes heart study). Am J Cardiol. 2013;111(8):1152–8.
11. Fabbian F, De Giorgi A, Monesi M, Pala M, Tiseo R, Misurati E, et al. All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: is there a relationship with the equation used? Diab Vasc Dis Res. 2015;12(1):46–52.
12. Grembowski D, Ralston JD, Anderson ML. Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: a retrospective 9-year cohort study. Diabetes Res Clin Pract. 2014;106(2):373–82.
13. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007;30(2):292–9.
14. Bot M, Pouwer F, Zuidersma M, van Melle JP, de Jonge P. Association of coexisting diabetes and depression with mortality after myocardial infarction. Diabetes Care. 2012;35(3):503–9.
15. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–71.
16. Sanchez Martinez M, Blanco A, Castell MV, Gutierrez Misis A, Gonzalez Montalvo JI, Zunzunegui MV, et al. Diabetes in older people: Prevalence, incidence and its association with medium- and long-term mortality from all causes. Aten Primaria. 2014;46(7):376–84.
17. Nanchen D, Rodondi N, Cornuz J, Hillier T, Ensrud KE, Cauley JA, et al. Mortality associated with diabetes and cardiovascular disease in older women. PLoS ONE. 2012;7(11):e48818.
18. Carrero JJ, de Mutsert R, Axelsson J, Dekkers OM, Jager KJ, Boeschoten EW, et al. Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26(1):270–6.
19. van Hateren KJ, Hendriks SH, Groenier KH, Bakker SJ, Bilo HJ, Kleefstra N, et al. Frailty and the relationship between blood pressure and mortality in elderly patients with type 2 diabetes (Zwolle Outpatient diabetes project Integrating available Care-34). J Hypertens. 2015;33(6):1162–6.
20. Egede LE, Lynch CP, Gebregziabher M, Hunt KJ, Echols C, Gilbert GE, et al. Differential impact of longitudinal medication non-adherence on mortality by race/ethnicity among veterans with diabetes. J Gen Intern Med. 2013;28(2):208–15.
21. Dupre ME, Silberberg M, Willis JM, Feinglos MN. Education, glucose control, and mortality risks among U.S. older adults with diabetes. Diabetes Res Clin Pract. 2015;107(3):392–9.
22. Landman GW, Kleefstra N, van Hateren KJ, Gans RO, Bilo HJ, Groenier KH. Educational disparities in mortality among patients with type 2 diabetes in the Netherlands (ZODIAC-23). Neth J Med. 2013;71(2):76–80.
23. Jackson CA, Jones NR, Walker JJ, Fischbacher CM, Colhoun HM, Leese GP, et al. Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia. 2012;55(11):2938–45.
24. Saydah SH, Imperatore G, Beckles GL. Socioeconomic status and mortality: contribution of health care access and psychological distress among U.S. adults with diagnosed diabetes. Diabetes Care. 2013;36(1):49–55.
25. Conway BN, May ME, Blot WJ. Mortality among low-income African Americans and whites with diabetes. Diabetes Care. 2012;35(11):2293–9.
26. Zahra A, Lee EW, Sun LY, Park JH. Cardiovascular disease and diabetes mortality, and their relation to socio-economical, environmental, and health behavioural factors in worldwide view. Public Health. 2015;129(4):385–95.
27. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. J Am Med Assoc. 2003;290(14):1884–90.
28. Shah BR, Victor JC, Chiu M, Tu JV, Anand SS, Austin PC, et al. Cardiovascular complications and mortality after diabetes diagnosis for South Asian and Chinese patients: a population-based cohort study. Diabetes Care. 2013;36(9):2670–6.
29. Jandorf S, Siersma V, Koster-Rasmussen R, de Fine ON, Waldorff FB. The impact of patients' involvement in cooking on their mortality and morbidity: a 19-year follow-up of patients diagnosed with type 2 diabetes mellitus. Scand J Prim Health Care. 2015;33(1):33–9.
30. Ylitalo KR, McEwen LN, Karter AJ, Lee P, Herman WH. Self-reported physical functioning and mortality among individuals with type 2 diabetes: insights from TRIAD. J Diabetes Complicat. 2013;27(6):565–9.
31. Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care. 2013;36(2):471–9.
32. Moe B, Augestad LB, Nilsen TI. Diabetes severity and the role of leisure time physical exercise on cardiovascular mortality: the Nord-Trondelag health study (HUNT). Norway Cardiovasc Diabetol. 2013;12:83.
33. Moe B, Eilertsen E, Nilsen TI. The combined effect of leisure-time physical activity and diabetes on cardiovascular mortality: the Nord-Trondelag health (HUNT) cohort study. Norway Diabetes Care. 2013;36(3):690–5.
34. Burger KN, Beulens JW, van der Schouw YT, Sluijs I, Spijkerman AM, Sluik D, et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS ONE. 2012;7(8):e43127.
35. Long GH, Cooper AJ, Wareham NJ, Griffin SJ, Simmons RK. Healthy behavior change and cardiovascular outcomes in newly diagnosed type 2 diabetic patients: a cohort analysis of the ADDITION-Cambridge study. Diabetes Care. 2014;37(6):1712–20.
36. Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Ten-year mortality and cardiovascular morbidity in the Finnish diabetes prevention study–secondary analysis of the randomized trial. PLoS ONE. 2009;4(5):e5656.
37. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
38. Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ. The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract. 2010;60(572):172–5.
39. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care. 2014;37(3):634–43.
40. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33(4):721–7.
41. Wong CK, Wong WC, Wan YF, Chan AK, Chung KL, Chan FW, et al. Patient empowerment Programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study. Diabetes Obes Metab. 2015;17(2):128–35.
42. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–901.
43. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–84.
44. Li Y, Lan L, Wang Y, Yang C, Tang W, Cui G, et al. Extremely cold and hot temperatures increase the risk of diabetes mortality in metropolitan areas of two Chinese cities. Environ Res. 2014;134:91–7.
45. Agarwal S, Cox AJ, Herrington DM, Jorgensen NW, Xu J, Freedman BI, et al. Coronary calcium score predicts cardiovascular mortality in diabetes: diabetes heart study. Diabetes Care. 2013;36(4):972–7.
46. Cox AJ, Hsu FC, Freedman BI, Herrington DM, Criqui MH, Carr JJ, et al. Contributors to mortality in high-risk diabetic patients in the diabetes heart study. Diabetes Care. 2014;37(10):2798–803.
47. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV, Strong HS. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004;53(2):434–40.
48. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126(15):1858–68.
49. Gholap NN, Mehta RL, Ng L, Davies MJ, Khunti K, Squire IB. Is admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than diabetes diagnosis? A retrospective cohort study. BMJ Open. 2012;2(5):1–9.
50. Park BS, Yoon JS, Moon JS, Won KC, Lee HW. Predicting mortality of critically ill patients by blood glucose levels. Diabetes Metab J. 2013;37(5):385–90.
51. Sechterberger MK, Bosman RJ, Oudemans-van Straaten HM, Siegelaar SE, Hermanides J, Hoekstra JB, et al. The effect of diabetes mellitus on the association between measures of glycaemic control and ICU mortality: a retrospective cohort study. Crit Care. 2013;17(2):R52.
52. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73.
53. Tsai CW, Grams ME, Inker LA, Coresh J, Selvin E. Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S. Diabetes Care. 2014;37(4):1002–8.
54. Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, et al. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. PLoS ONE. 2013;8(8):e71810.
55. Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S. Swedish National Diabetes R. albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National diabetes Register. Diab Vasc Dis Res. 2013;10(6):520–9.
56. Cox AJ, Hsu FC, Carr JJ, Freedman BI, Bowden DW. Glomerular filtration rate and albuminuria predict mortality independently from coronary artery calcified plaque in the diabetes heart study. Cardiovasc Diabetol. 2013;12:68.
57. Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, et al. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabetes Care. 2013;36(6):1489–94.
58. Osthus TB, von der Lippe N, Ribu L, Rustoen T, Leivestad T, Dammen T, et al. Health-related quality of life and all-cause mortality in patients with diabetes on dialysis. BMC Nephrol. 2012;13:78.
59. Sattar A, Argyropoulos C, Weissfeld L, Younas N, Fried L, Kellum JA, et al. All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrol. 2012;13:130.
60. Kong AP, Yang X, Luk A, Cheung KK, Ma RC, So WY, et al. Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocr Disord. 2014;14:48.
61. Lynch CP, Gebregziabher M, Zhao Y, Hunt KJ, Egede LE. Impact of medical and psychiatric multi-morbidity on mortality in diabetes: emerging evidence. BMC Endocr Disord. 2014;14:68.
62. Coleman SM, Katon W, Lin E, Von Korff M. Depression and death in diabetes; 10-year follow-up of all-cause and cause-specific mortality in a diabetic cohort. Psychosomatics. 2013;54(5):428–36.
63. Ribe AR, Laursen TM, Sandbaek A, Charles M, Nordentoft M, Vestergaard M. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med. 2014;44(14):3097–107.
64. Fedeli U, Zoppini G, Gennaro N, Saugo M. Diabetes and cancer mortality: a multifaceted association. Diabetes Res Clin Pract. 2014;106(3):e86–9.
65. Tseng CH. Diabetes but not insulin is associated with higher colon cancer mortality. World J Gastroenterol. 2012;18(31):4182–90.
66. van de Poll-Franse LV, Haak HR, Coebergh JW, Janssen-Heijnen ML, Lemmens VE. Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia. 2012;55(8):2163–72.
67. Chiou WK, Hwang JS, Hsu KH, Lin JD. Diabetes mellitus increased mortality rates more in gender-specific than in nongender-specific cancer patients: a retrospective study of 149,491 patients. Exp Diabetes Res. 2012;2012:701643.
68. Zhou Y, Zhang X, Gu C, Xia J. Influence of diabetes mellitus on mortality in breast cancer patients. ANZ J Surg. 2014;85:972–978.
69. Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G, et al. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore). 2014;93(27):e183.
70. Chen ST, Hsueh C, Chiou WK, Lin JD. Disease-specific mortality and secondary primary cancer in well-differentiated thyroid cancer with type 2 diabetes mellitus. PLoS ONE. 2013;8(1):e55179.
71. Kiderlen M, de Glas NA, Bastiaannet E, Engels CC, van de Water W, de Craen AJ, et al. Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann Oncol. 2013;24(12):3011–6.
72. Psutka SP, Stewart SB, Boorjian SA, Lohse CM, Tollefson MK, Cheville JC, et al. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J Urol. 2014;192(6):1620–7.
73. Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, et al. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015;111(6):740–5.
74. Conway BN, May ME, Fischl A, Frisbee J, Han X, Blot WJ. Cause-specific mortality by race in low-income Black and White people with type 2 diabetes. Diabet Med. 2015;32(1):33–41.
75. Liu J. Impact of diabetes mellitus on pneumonia mortality in a senior population: results from the NHANES III follow-up study. J Geriatr Cardiol. 2013;10(3):267–71.
76. Poole CD, Halcox JP, Jenkins-Jones S, Carr ES, Schifflers MG, Ray KK, et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. Clin Ther. 2013;35(1):40–51.
77. Logue J, Walker JJ, Leese G, Lindsay R, McKnight J, Morris A, et al. Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care. 2013;36(4):887–93.
78. Ma SH, Park BY, Yang JJ, Jung EJ, Yeo Y, Whang Y, et al. Interaction of body mass index and diabetes as modifiers of cardiovascular mortality in a cohort study. J Prev Med Public Health. 2012;45(6):394–401.
79. Murphy RA, Reinders I, Garcia ME, Eiriksdottir G, Launer LJ, Benediktsson R, et al. Adipose tissue, muscle, and function: potential mediators of associations between body weight and mortality in older adults with type 2 diabetes. Diabetes Care. 2014;37(12):3213–9.
80. Lajous M, Bijon A, Fagherazzi G, Boutron-Ruault MC, Balkau B, Clavel-Chapelon F, et al. Body mass index, diabetes, and mortality in French women: explaining away a “paradox”. Epidemiology. 2014;25(1):10–4.
81. Jackson CL, Yeh HC, Szklo M, Hu FB, Wang NY, Dray-Spira R, et al. Body-Mass index and all-cause mortality in US adults with and without diabetes. J Gen Intern Med. 2014;29(1):25–33.
82. Suemoto CK, Lebrao ML, Duarte YA, Danaei G. Effects of body mass index, abdominal obesity, and type 2 diabetes on mortality in community-dwelling elderly in Sao Paulo, Brazil: analysis of prospective data from the SABE study. J Gerontol A Biol Sci Med Sci. 2015;70(4):503–10.
83. Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. J Am Med Assoc. 2012;308(6):581–90.
84. Menke A, Casagrande SS, Cowie CC. The relationship of adiposity and mortality among people with diabetes in the US general population: a prospective cohort study. BMJ Open. 2014;4(11):e005671.
85. Franco M, Bilal U, Ordunez P, Benet M, Morejon A, Caballero B, et al. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ. 2013;346:f1515.
86. Bodegard J, Sundstrom J, Svennblad B, Ostgren CJ, Nilsson PM, Johansson G. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab. 2013;39(4):306–13.
87. Sluik D, Boeing H, Montonen J, Pischon T, Kaaks R, Teucher B, et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011;174(1):22–34.
88. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499–504.
89. Bozorgmanesh M, Arshi B, Sheikholeslami F, Azizi F, Hadaegh F. No obesity Paradox-BMI Incapable of Adequately Capturing the relation of obesity with all-cause mortality: an Inception diabetes cohort study. Int J Endocrinol. 2014;2014:282089.
90. Nayak AU, Nevill AM, Bassett P, Singh BM. Association of glycation gap with mortality and vascular complications in diabetes. Diabetes Care. 2013;36(10):3247–53.
91. Bancks MP, Odegaard AO, Pankow JS, Koh WP, Yuan JM, Gross MD, et al. Glycated hemoglobin and all-cause and cause-specific mortality in Singaporean Chinese without diagnosed diabetes: the Singapore Chinese health study. Diabetes Care. 2014;37(12):3180–7.
92. Sluik D, Boeing H, Montonen J, Kaaks R, Lukanova A, Sandbaek A, et al. HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus. PLoS ONE. 2012;7(6):e38877.
93. Gordon-Dseagu VL, Mindell JS, Steptoe A, Moody A, Wardle J, Demakakos P, et al. Impaired glucose metabolism among those with and without diagnosed diabetes and mortality: a cohort study using health Survey for England data. PLoS ONE. 2015;10(3):e0119882.
94. Twito O, Ahron E, Jaffe A, Afek S, Cohen E, Granek-Catarivas M, et al. New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. Diabetes Care. 2013;36(11):3425–9.
95. Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud. 2014;11(2):138–52.
96. Nicholas J, Charlton J, Dregan A, Gulliford MC. Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study. PLoS One. 2013;8(7):e68008.
97. Skriver MV, Sandbaek A, Kristensen JK, Stovring H. Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study. BMJ Open Diabetes Res Care. 2015;3(1):e000060.
98. Twito O, Frankel M, Nabriski D. Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetes. World J Diabetes. 2015;6(2):345–51.
99. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316–22.
100. Huang CC, Weng SF, Tsai KT, Chen PJ, Lin HJ, Wang JJ, et al. Long-term mortality risk after Hyperglycemic Crisis Episodes in Geriatric patients with diabetes: A National Population-Based Cohort Study. Diabetes Care. 2015;38(5):746–51.
101. Viana MV, Moraes RB, Fabbrin AR, Santos MF, Torman VB, Vieira SR, et al. Contrasting effects of preexisting hyperglycemia and higher body size on hospital mortality in critically ill patients: a prospective cohort study. BMC Endocr Disord. 2014;14:50.
102. Chen KH, Shao YY, Lin ZZ, Yeh YC, Shau WY, Kuo RN, et al. Type 2 diabetes mellitus is associated with increased mortality in Chinese patients receiving curative surgery for colon cancer. Oncologist. 2014;19(9):951–8.
103. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care. 2008;31(9):1761–6.
104. Afghahi H, Svensson MK, Pirouzifard M, Eliasson B, Svensson AM. Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. Diabetologia. 2015;58(6):1203–11.
105. Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, et al. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ. 2012;345:e5567.
106. Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol. 2014;13:135.
107. Xu Y, Zhu J, Gao L, Liu Y, Shen J, Shen C, et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS ONE. 2013;8(10):e78206.
108. Kengne AP, Czernichow S, Hamer M, Batty GD, Stamatakis E. Anaemia, haemoglobin level and cause-specific mortality in people with and without diabetes. PLoS ONE. 2012;7(8):e41875.
109. Potier L, Roussel R, Labreuche J, Marre M, Cacoub P, Rother J, et al. Interaction between diabetes and a high ankle-brachial index on mortality risk. Eur J Prev Cardiol. 2015;22(5):615–21.
110. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.
111. Pikkemaat M, Melander O, Molstad S, Garberg G, Bostrom KB. C-peptide concentration, mortality and vascular complications in people with type 2 diabetes. The Skaraborg Diabetes Register Diabet Med. 2015;32(1):85–9.
112. Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63(3):1115–23.
113. Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, et al. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Baerum cardiovascular diabetes (ABCD) cohort study. Cardiovasc Diabetol. 2013;12:126.
114. Bruno G, Landi A, Barutta F, Ghezzo G, Baldin C, Spadafora L, et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care. 2013;36(9):2677–82.
115. Cheung CL, Lam KS, Cheung BM. Serum beta-2 microglobulin predicts mortality in people with diabetes. Eur J Endocrinol. 2013;169(1):1–7.
116. Cavusoglu E, Marmur JD, Chhabra S, Hojjati MR, Yanamadala S, Chopra V, et al. Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease. Atherosclerosis. 2015;239(2):503–8.
117. Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, et al. Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS ONE. 2013;8(3):e58007.
118. Drion I, Kleefstra N, Landman GW, Alkhalaf A, Struck J, Groenier KH, et al. Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29). Diabetes Care. 2012;35(11):2354–8.
119. van Hateren KJ, Landman GW, Kleefstra N, Groenier KH, Struck J, Navis GJ, et al. The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25). Diabetes Care. 2013;36(5):1347–52.
120. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT, et al. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. Diabetes Care. 2013;36(3):669–76.
121. Landman GW, van Vliet-Ostaptchouk JV, Kleefstra N, van Hateren KJ, Drion I, Groenier KH, et al. Association between 9p21 genetic variants and mortality risk in a prospective cohort of patients with type 2 diabetes (ZODIAC-15). Cardiovasc Diabetol. 2012;11:138.
122. Prudente S, Shah H, Bailetti D, Pezzolesi M, Buranasupkajorn P, Mercuri L, et al. Genetic Variant at the GLUL Locus predicts all-cause mortality in patients with type 2 diabetes. Diabetes. 2015;64(7):2658–63.
123. Cox AJ, Hsu FC, Ng MC, Langefeld CD, Freedman BI, Carr JJ, et al. Genetic risk score associations with cardiovascular disease and mortality in the diabetes heart study. Diabetes Care. 2014;37(4):1157–64.
124. Armstrong MJ, Sigal RJ, Arena R, Hauer TL, Austford LD, Aggarwal S, et al. Cardiac rehabilitation completion is associated with reduced mortality in patients with diabetes and coronary artery disease. Diabetologia. 2015;58(4):691–8.
125. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
126. Mogensen UM, Andersson C, Fosbol EL, Schramm TK, Vaag A, Scheller NM, et al. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality–a retrospective nationwide study. Diabetes Res Clin Pract. 2015;107(1):104–12.
127. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31(25):3069–75.
128. Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16(11):1165–73.
129. Christiansen C, Johansen M, Christensen S, O'Brien JM, Tonnesen E, Sorensen H. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care. 2013;17(5):R192.
130. Vissers PA, Cardwell CR, van de Poll-Franse LV, Young IS, Pouwer F, Murray LJ. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res Treat. 2015;150(2):427–37.
131. Gu Y, Wang C, Zheng Y, Hou X, Mo Y, Yu W, et al. Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai. PLoS ONE. 2013;8(1):e53411.
132. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650–61.
133. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015;17(4):350–62.
134. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668–77.
135. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. J Am Med Assoc. 2014;311(22):2288–96.
136. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99(8):1926–35.
137. Rison RA, Kidd MR, Koch CA. The CARE (CAse REport) guidelines and the standardization of case reports. J Med Case Rep. 2013;7:261.